Resumption of Trading for Inventiva Shares
Inventiva, a clinical-stage biopharmaceutical company specializing in oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), has officially announced the resumption of trading for its ordinary shares on Euronext Paris. The trading resumed at 4:30 p.m. CET after a previous halt requested by the company.
Details of the Trading Halt
The temporary suspension of trading, which began at 9:00 a.m. CET, was part of the company's ongoing public offering exclusively in the United States, concerning newly issued American Depositary Shares. These shares represented the company's ordinary shares with a nominal value of €0.01. The halt was essential to finalize allocations to investors and disclose the offering pricing.
About Inventiva
Inventiva is a forward-thinking company in the biopharmaceutical sector, committed to developing novel therapies for MASH, which affects many adults globally and can lead to severe liver problems. At present, the company is conducting the NATiV3 pivotal Phase 3 clinical trial to evaluate the efficacy of lanifibranor, a pan-PPAR agonist, aimed at delivering innovative treatment options for patients suffering from this condition.
Listed Markets and Stock Tickers
The company is publicly traded in multiple regions, listed on Euronext Paris with the ticker symbol IVA and also on the Nasdaq Global Market in the United States under the same ticker. Additionally, it is identified by the OTC ticker IVEVF, allowing investors access to its shares across different platforms and increasing its market visibility.
Company Contacts
For media inquiries or further information, interested parties can contact Pascaline Clerc, EVP of Strategy and Corporate Affairs at Inventiva. She can be reached via email at media@inventivapharma.com or by phone at +1 202 499 8937.
Furthermore, for investor relations, Patricia L. Bank is available by email at patti.bank@icrhealthcare.com or by calling +1 415 513 1284. This provides a direct line for queries relating to the company’s financial performance and future outlook.
Moving Forward
As Inventiva continues to advance its research and clinical trials, the resumption of trading is a positive development not just for the company but also for investors and stakeholders looking to support innovations in healthcare. The company remains committed to pushing boundaries in the biopharmaceutical landscape with its focus on MASH treatment options.
Frequently Asked Questions
What is Inventiva's primary focus?
Inventiva focuses on developing oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
When did trading resume for Inventiva shares?
Trading for Inventiva's ordinary shares resumed at 4:30 p.m. CET after a brief halt.
What triggered the trading halt?
The halt was triggered by the company's need to finalize allocations for its public offering of American Depositary Shares in the U.S.
Which markets does Inventiva trade on?
Inventiva trades on Euronext Paris under the ticker IVA and on Nasdaq as well.
Who are the key contacts at Inventiva for inquiries?
Pascaline Clerc for media inquiries and Patricia L. Bank for investor relations are the key contacts.
